Faculty

Steven Pergam

Adjunct Associate Professor, Epidemiology
Associate Professor, Medicine - Allergy and Infectious Dis.


spergam@fredhutch.org

Education

MD University of Nebraska, 1998
MPH Epidemiology, University of Washington, 2008

Contact


spergam@fredhutch.org

Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave. N, E4-100
Seattle, WA 98109
View Website »

Bio

Dr. Pergam is an Infectious Diseases physician and researcher who received his MD from the University of Nebraska School of Medicine, his Infectious Diseases fellowship training at the University of Washington (UW), and his MPH from the UW School of Public Health. Dr. Pergam serves as the Medical Director of Infection Prevention at the Seattle Cancer Care Alliance (SCCA). Dr. Pergam focuses his research on the prevention and treatment of infections among immunocompromised patients, and has expertise in infection prevention and hospital epidemiology among cancer and transplant patients. He serves on numerous national committees, including the CDC’s Advisory Committee on Immunization Practices, and the National Comprehensive Cancer Network Committee on the Prevention and Treatment of Infections in Cancer. He also is an Associate Editor for BMC Infectious Diseases and Current Opinions in Infectious Diseases.

Research Interests

Dr. Pergam’s research interests involve hospital epidemiology, antimicrobial resistance, and infection prevention in immunosuppressed hosts. His research group focuses on infection prevention, resistant pathogens, antimicrobial stewardship, and on the development of novel prevention strategies for community and healthcare-associated infections in cancer and hematopoietic cell transplant patients. He has active research projects that evaluate vaccinations, water-borne pathogens, resistant bacteria, respiratory virus transmission, and fungal infections among immunocompromised hosts. He is interested in the interplay between the immune response, the microbiome, bacterial and viral infections in the respiratory and gastrointestinal systems, and their association with inflammatory complications (e.g. Graft-versus-host disease, mucositis).

Recent Publications (PubMed)

Antibiotic prescribing knowledge: A brief survey of providers and staff at an ambulatory cancer center during Antibiotic Awareness Week 2019.
(2022)
Antimicrob Steward Healthc Epidemiol 2(1): e18
Gulleen EA, Krantz EM, Zier J, Bhattacharyya P, Kates O, So L, Sweet A, Yoke LH, Pergam SA, Liu C

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
(2022 Oct 21)
Transplant Cell Ther
Khawaja F, Papanicolaou G, Dadwal S, Pergam SA, Wingard JR, Boghdadly ZE, Abidi MZ, Waghmare A, Shahid Z, Michaels L, Hill JA, Kamboj M, Boeckh M, Auletta JJ, Chemaly RF

Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant.
(2022 Dec)
Bone Marrow Transplant 57(12): 1765-1773
Ogimi C, Krantz EM, Golob JL, Liu C, Waghmare A, Akramoff A, Mallory A, Leisenring WM, Jerome KR, Chow VA, Pergam SA, Fredricks DN, Englund JA, Boeckh M

Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center.
(2022 Aug)
Transplant Cell Ther 28(8): 511.e1-511.e10
Lindsay J, Krantz EM, Morris J, Sweet A, Tverdek F, Joshi A, Yeh R, Hill JA, Greenwood M, Chen SC, Kong DCM, Slavin M, Pergam SA, Liu C

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
(2021 Nov)
Open Forum Infect Dis 8(11): ofab502
Lindsay J, Othman J, Kong Y, Yip A, Van Hal S, Larsen S, Bryant C, Gibson J, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SCA, Kong DCM, Greenwood M, Pergam SA, Liu C, Slavin MA

Show complete publication list